\-\ Texto\\:\\ \ \(0\)\
\-\ cranial\\ nerves\\ intact\\.\ \(0\)\
\-\ normal\\ laboratory\\ evaluation\ \(0\)\
\-\ radiation\\ therapy\ \(165\)\
\-\ \\â\\€\\¢\\ multifocal\\ enhancing\\ masses\\ in\\ midbrain\\,\\ pons\\ and\\ medulla\\.\ \(0\)\
\-\ \\â\\€\\¢\\ homogeneous\\ enhancement\\ following\\ contrast\\.\ \(0\)\
\-\ \\â\\€\\¢\\ no\\ hydrocephalus\\.\ \(0\)\
\-\ anaplastic\\ astrocytoma\ \(4\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ \\â\\€\\¢\\ sarcoidosis\ \(1\)\
\-\ \\â\\€\\¢\\ multiple\\ sclerosis\ \(0\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ multi\\-centric\\ glioma\ \(0\)\
\-\ 44\\ year\\ old\\ man\\ presents\\ with\\ one\\ week\\ history\\ of\\ paresthesia\\,\\ ataxia\\ and\\ slurred\\ speech\\.\ \(1\)\
\-\ brainstem\\ gliomas\\ are\\ quite\\ unusual\\ in\\ adults\\.\ \(0\)\
\-\ most\\ such\\ lesions\\ are\\ not\\ anaplastic\\ and\\ typically\\ present\\ in\\ children\\.\\ \\ the\\ new\\ who\\ classification\\ \\(2007\\)\\ indicates\\ that\\ any\\ vascular\\ changes\\ upgrade\\ the\\ neoplasm\\ from\\ anaplastic\\ to\\ gbm\\.\\ \\ thus\\,\\ contrast\\ enhancement\\ should\\ be\\ viewed\\ as\\ a\\ very\\ ominous\\ finding\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ anaplastic\\:\\ 0\\.1403877709429918\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.10900969402406177\ \(0\)\
\-\ upgrade\\:\\ 0\\.07665668194753476\ \(0\)\
\-\ multi\\-centric\\:\\ 0\\.07062931516005698\ \(0\)\
\-\ ominous\\:\\ 0\\.0646019483725792\ \(0\)\
\-\ paresthesia\\:\\ 0\\.055048798036334765\ \(0\)\
\-\ viewed\\:\\ 0\\.05435277449134749\ \(0\)\
\-\ slurred\\:\\ 0\\.05370835734218469\ \(0\)\
\-\ medulla\\:\\ 0\\.049021431248856974\ \(0\)\
\-\ gliomas\\:\\ 0\\.049021431248856974\ \(0\)\
\-\ midbrain\\:\\ 0\\.04679592364766393\ \(0\)\
\-\ quite\\:\\ 0\\.04479962415510306\ \(0\)\
\-\ gbm\\:\\ 0\\.04395059398498205\ \(0\)\
\-\ indicates\\:\\ 0\\.043750685130854235\ \(0\)\
\-\ speech\\:\\ 0\\.04281476631179019\ \(0\)\
\-\ pons\\:\\ 0\\.04246689383688845\ \(0\)\
\-\ classification\\:\\ 0\\.04246689383688845\ \(0\)\
\-\ 2007\\:\\ 0\\.041969864151323685\ \(0\)\
\-\ brainstem\\:\\ 0\\.04165362376722912\ \(0\)\
\-\ multifocal\\:\\ 0\\.03996531059817732\ \(0\)\
\-\ enhancement\\:\\ 0\\.03983458723692237\ \(0\)\
\-\ ataxia\\:\\ 0\\.03971324506014903\ \(0\)\
\-\ 44\\:\\ 0\\.03812784021846247\ \(0\)\
\-\ adults\\:\\ 0\\.03792322719750426\ \(0\)\
\-\ nerves\\:\\ 0\\.03772331834337645\ \(0\)\
\-\ thus\\:\\ 0\\.036966697673901414\ \(0\)\
\-\ unusual\\:\\ 0\\.0359424973638459\ \(0\)\
\-\ homogeneous\\:\\ 0\\.03517246782174638\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.033562533620567284\ \(0\)\
\-\ glioma\\:\\ 0\\.03350151124962253\ \(0\)\
\-\ contrast\\:\\ 0\\.033265664118398354\ \(0\)\
\-\ cranial\\:\\ 0\\.032310017357759124\ \(0\)\
\-\ children\\:\\ 0\\.03210047343098469\ \(0\)\
\-\ hydrocephalus\\:\\ 0\\.03194656406490294\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.02885521911889823\ \(0\)\
\-\ laboratory\\:\\ 0\\.02738340639873101\ \(0\)\
\-\ intact\\:\\ 0\\.02729360540607145\ \(0\)\
\-\ very\\:\\ 0\\.02697204885614895\ \(0\)\
\-\ sclerosis\\:\\ 0\\.026689697681968216\ \(0\)\
\-\ typically\\:\\ 0\\.02622978930005193\ \(0\)\
\-\ new\\:\\ 0\\.0258938084939179\ \(0\)\
\-\ neoplasm\\:\\ 0\\.025305709355755896\ \(0\)\
\-\ week\\:\\ 0\\.02523491668111503\ \(0\)\
\-\ masses\\:\\ 0\\.025118194765183368\ \(0\)\
\-\ radiation\\:\\ 0\\.0243847934744551\ \(0\)\
\-\ vascular\\:\\ 0\\.024363506677597364\ \(0\)\
\-\ finding\\:\\ 0\\.0239483609133781\ \(0\)\
\-\ should\\:\\ 0\\.023688769929467828\ \(0\)\
\-\ any\\:\\ 0\\.023398565504976467\ \(0\)\
\-\ enhancing\\:\\ 0\\.0233039437642153\ \(0\)\
\-\ such\\:\\ 0\\.023228980781224803\ \(0\)\
\-\ evaluation\\:\\ 0\\.021584685181102677\ \(0\)\
\-\ changes\\:\\ 0\\.021296069358565744\ \(0\)\
\-\ lymphoma\\:\\ 0\\.021236509864256396\ \(0\)\
\-\ following\\:\\ 0\\.02108937179914042\ \(0\)\
\-\ are\\:\\ 0\\.020258676043993073\ \(0\)\
\-\ one\\:\\ 0\\.02013679463748386\ \(0\)\
\-\ lesions\\:\\ 0\\.01989183048994737\ \(0\)\
\-\ therapy\\:\\ 0\\.019866441706440113\ \(0\)\
\-\ who\\:\\ 0\\.019373638340362626\ \(0\)\
\-\ metastatic\\:\\ 0\\.018705299161879047\ \(0\)\
\-\ man\\:\\ 0\\.017573320374695646\ \(0\)\
\-\ most\\:\\ 0\\.017155088188939793\ \(0\)\
\-\ present\\:\\ 0\\.016782684816797226\ \(0\)\
\-\ multiple\\:\\ 0\\.015650486986776253\ \(0\)\
\-\ presents\\:\\ 0\\.015179515613112399\ \(0\)\
\-\ that\\:\\ 0\\.01283461503094629\ \(0\)\
\-\ disease\\:\\ 0\\.012145543836658296\ \(0\)\
\-\ normal\\:\\ 0\\.011648803953035662\ \(0\)\
\-\ be\\:\\ 0\\.011458754116034166\ \(0\)\
\-\ as\\:\\ 0\\.011239804399079373\ \(0\)\
\-\ from\\:\\ 0\\.011012484462210542\ \(0\)\
\-\ in\\:\\ 0\\.010992971221050129\ \(0\)\
\-\ not\\:\\ 0\\.010737553667321178\ \(0\)\
\-\ history\\:\\ 0\\.010262735110496378\ \(0\)\
\-\ year\\:\\ 0\\.008313958863242737\ \(0\)\
\-\ old\\:\\ 0\\.007608126929236997\ \(0\)\
\-\ no\\:\\ 0\\.007482123049598278\ \(0\)\
\-\ \\,\\:\\ 0\\.007062001709146627\ \(0\)\
\-\ \\(\\:\\ 0\\.006281406315164005\ \(0\)\
\-\ \\)\\:\\ 0\\.006204675583593958\ \(0\)\
\-\ and\\:\\ 0\\.004695887106057873\ \(0\)\
\-\ to\\:\\ 0\\.003713635725591185\ \(0\)\
\-\ a\\:\\ 0\\.0034486939288574025\ \(0\)\
\-\ \\.\\:\\ 0\\.0027782245641401436\ \(0\)\
\-\ the\\:\\ 0\\.002404335386150014\ \(0\)\
\-\ with\\:\\ 0\\.0010174276181729542\ \(0\)\
\-\ of\\:\\ 0\\.0010130765286781602\ \(0\)\
